Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
72 hedge funds and large institutions have $76.6M invested in Enzo Biochem, Inc. in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 33 reducing their positions, and 26 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% less funds holding
Funds holding: 82 → 72 (-10)
19% less capital invested
Capital invested by funds: $94.5M → $76.6M (-$17.9M)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
73% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 33
91% less call options, than puts
Call options by funds: $343K | Put options by funds: $3.85M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCA
VIEX Capital Advisors
Sunny Isles Beach,
Florida
|
+$4.71M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$2.98M |
| 3 |
Millennium Management
New York
|
+$997K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
+$830K |
| 5 |
E
Ergoteles
New York
|
+$607K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.42M |
| 2 |
EGA
Evermore Global Advisors
Summit,
New Jersey
|
-$2.75M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.18M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.09M |
ENZ Hedge Fund Activity: Q2 2021 in Review
72 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q2 2021, worth a combined $76.6M — down 19% from $94.5M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ENZ and 16 opened new positions — a net loss of 10 holders — while 33 trimmed existing stakes and 9 added.
The largest buyer was VIEX Capital Advisors, opening a new position worth an estimated $4.71M. The largest seller was BlackRock, cutting an estimated $7.42M.
- 72 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q2 2021, down from 82 in Q1 2021.
- Funds reported $76.6M of Enzo Biochem, Inc. stock for Q2 2021, down 19% quarter-over-quarter.
- 16 funds opened new Enzo Biochem, Inc. positions in Q2 2021 and 26 closed out, a net change of -10 holders.
- The largest Enzo Biochem, Inc. buyer in Q2 2021 was VIEX Capital Advisors, an estimated $4.71M added.
- The largest Enzo Biochem, Inc. seller in Q2 2021 was BlackRock, an estimated $7.42M sold.
Based on aggregated 13F filings for Q2 2021.